{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:17:24Z","timestamp":1793121444003,"version":"4.5.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP.02\/725\/46"],"award-info":[{"award-number":["RGP.02\/725\/46"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.retram.2025.103561","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:13:56Z","timestamp":1765818836000},"page":"103561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel): Bridging pharmacology and translational medicine in breast cancer"],"prefix":"10.1016","volume":"74","author":[{"given":"Ali G.","family":"Alkhathami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman T.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopashree","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakhar","family":"Tomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein Riyadh Abdul Kareem","family":"Al-Hetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashree","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Singh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi Jihad","family":"Hammady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah Abdulhadi","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.retram.2025.103561_bib0001","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/1568009620666200331124113","article-title":"Nanomedicine: a promising avenue for the development of effective therapy for breast cancer","volume":"20","author":"Sartaj","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052856","article-title":"Nanomedicine-based delivery strategies for breast cancer treatment and management","volume":"23","author":"Tagde","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.retram.2025.103561_bib0003","doi-asserted-by":"crossref","unstructured":"Collaborators G: global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Available at SSRN 5533924 2025.","DOI":"10.2139\/ssrn.5533924"},{"issue":"10","key":"10.1016\/j.retram.2025.103561_bib0004","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.lpm.2019.09.022","article-title":"Breast cancer epidemiology","volume":"48","author":"Sancho-Garnier","year":"2019","journal-title":"Presse Medicale (Paris, France: 1983)"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0005","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/GRF.0000000000000239","article-title":"Breast cancer epidemiology and risk factors","volume":"59","author":"Rojas","year":"2016","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.retram.2025.103561_bib0006","article-title":"Subtypes of breast cancer","author":"Orrantia-Borunda","year":"2022","journal-title":"Breast Cancer [Internet]"},{"issue":"15","key":"10.1016\/j.retram.2025.103561_bib0007","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1517\/14656566.9.15.2603","article-title":"Paclitaxel and docetaxel in the treatment of breast cancer","volume":"9","author":"Saloustros","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.retram.2025.103561_bib0008","article-title":"Paclitaxel resistance in breast cancer: current challenges and recent advanced therapeutic strategies","volume":"43","author":"Abouzeid","year":"2025","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tjog.2023.11.005","article-title":"Front-line chemoimmunotherapy for treating epithelial ovarian cancer: part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwanese J Obstetrics Gynecol"},{"issue":"10496","key":"10.1016\/j.retram.2025.103561_bib0010","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.retram.2025.103561_bib0011","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1016\/S2666-7568(21)00255-5","article-title":"Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial","volume":"2","author":"Kogure","year":"2021","journal-title":"Lancet Healthy Longevity"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0012","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.annonc.2020.10.479","article-title":"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial","volume":"32","author":"Shi","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0014","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-016-3778-z","article-title":"Neoadjuvant nab-paclitaxel in the treatment of breast cancer","volume":"156","author":"Ueno","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"40","key":"10.1016\/j.retram.2025.103561_bib0015","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1080\/14796694.2024.2431479","article-title":"Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis","volume":"20","author":"Zhang","year":"2024","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.retram.2025.103561_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/biom9120789","article-title":"Paclitaxel's mechanistic and clinical effects on breast cancer","volume":"9","author":"Abu Samaan","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.retram.2025.103561_bib0017","article-title":"Paclitaxel resistance in breast cancer: current challenges and recent advanced therapeutic strategies","volume":"43","author":"Abouzeid","year":"2025","journal-title":"Cancer Treat Res Commun"},{"issue":"10","key":"10.1016\/j.retram.2025.103561_bib0018","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/1389557520999201214234421","article-title":"Resistance to intervention: paclitaxel in breast cancer","volume":"21","author":"Dan","year":"2021","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0019","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12935-014-0142-4","article-title":"Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells","volume":"14","author":"Xu","year":"2014","journal-title":"Cancer Cell Int."},{"issue":"20","key":"10.1016\/j.retram.2025.103561_bib0020","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.7314\/APJCP.2014.15.20.8617","article-title":"Roles of the bcl-2\/bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel","volume":"15","author":"Sharifi","year":"2014","journal-title":"Asian Pacific J Cancer Prevention"},{"issue":"6","key":"10.1016\/j.retram.2025.103561_bib0021","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1634\/theoncologist.3-6-373","article-title":"Paclitaxel in breast cancer","volume":"3","author":"Perez","year":"1998","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.retram.2025.103561_bib0022","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.3390\/cancers12082252","article-title":"Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast cancer","volume":"12","author":"Varghese","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0023","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10863-013-9519-7","article-title":"Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin","volume":"45","author":"Tavares-Valente","year":"2013","journal-title":"J. Bioenerg. Biomembr."},{"issue":"643","key":"10.1016\/j.retram.2025.103561_bib0024","doi-asserted-by":"crossref","first-page":"eabl3649","DOI":"10.1126\/scitranslmed.abl3649","article-title":"Albumin nanoparticle containing a PI3K\u03b3 inhibitor and paclitaxel in combination with \u03b1-PD1 induces tumor remission of breast cancer in mice","volume":"14","author":"Song","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.retram.2025.103561_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104151","article-title":"Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases","volume":"82","author":"Ceelen","year":"2022","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.retram.2025.103561_bib0026","first-page":"1948","article-title":"Clinical experience of nab-Paclitaxel treatment in 31 patients with breast cancer]","volume":"41","author":"Tauchi","year":"2014","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.retram.2025.103561_bib0027","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.breast.2020.12.002","article-title":"Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer","volume":"55","author":"Tsurutani","year":"2021","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.retram.2025.103561_bib0029","article-title":"Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K\/AKT pathway through the Serpinc1 gene","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/bjc.2016.215","article-title":"Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer","volume":"115","author":"Rajeshkumar","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0031","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5152\/ejbh.2018.4174","article-title":"QOL evaluation of Nab-Paclitaxel and Docetaxel for early breast cancer","volume":"14","author":"Okuyama","year":"2018","journal-title":"Eur J Breast Health"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0032","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12282-021-01290-5","article-title":"Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer","volume":"29","author":"Taira","year":"2022","journal-title":"Breast Cancer"},{"issue":"10257","key":"10.1016\/j.retram.2025.103561_bib0033","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.retram.2025.103561_bib0034","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0036","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J Control Release"},{"issue":"14","key":"10.1016\/j.retram.2025.103561_bib0037","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/1078-0432.CCR-20-0668","article-title":"Atezolizumab plus Nab-paclitaxel in PD-L1-positive TNBC-letter","volume":"26","author":"Bravaccini","year":"2020","journal-title":"Clin Cancer Res: Official J Am Association Cancer Res"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0038","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","article-title":"De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial","volume":"26","author":"Chen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.retram.2025.103561_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102975","article-title":"Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: a systematic review and meta-analysis","volume":"138","author":"Yuan","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.retram.2025.103561_bib0041","first-page":"677","article-title":"[Neoadjuvant Epirubicin-Cyclophosphamide Therapy followed by Nab-Paclitaxel in Patients with Operable Breast Cancer-A Single-Center Phase \u2161 Trial]","volume":"49","author":"Ogata","year":"2022","journal-title":"Gan To Kagaku Ryoho"},{"issue":"8","key":"10.1016\/j.retram.2025.103561_bib0042","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.21873\/anticanres.15185","article-title":"Phase II study of Nab-paclitaxel plus Cyclophosphamide plus Trastuzumab neoadjuvant chemotherapy in early HER-2-positive breast cancer","volume":"41","author":"Ogino","year":"2021","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.retram.2025.103561_bib0043","first-page":"4213","article-title":"Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer","volume":"34","author":"Ohno","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.retram.2025.103561_bib0044","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s11658-019-0164-y","article-title":"Progress in research on paclitaxel and tumor immunotherapy","volume":"24","author":"Zhu","year":"2019","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.retram.2025.103561_bib0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jare.2022.09.007","article-title":"Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells","volume":"49","author":"Zhu","year":"2023","journal-title":"J Adv Res"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0046","doi-asserted-by":"crossref","first-page":"596","DOI":"10.20517\/cdr.2023.19","article-title":"Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7","volume":"6","author":"Apollonova","year":"2023","journal-title":"Cancer Drug Resistance"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0047","first-page":"400","article-title":"Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells","volume":"44","author":"Zhao","year":"2015","journal-title":"Zhejiang da xue xue bao Yi xue ban= J Zhejiang Univer Med Sci"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0048","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13058-014-0434-6","article-title":"Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential","volume":"16","author":"Pelicano","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0049","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/ecp.11.7","article-title":"Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review","volume":"4","author":"Montero","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.retram.2025.103561_bib0050","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","article-title":"Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel","volume":"14","author":"Gardner","year":"2008","journal-title":"Clin Cancer Research"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0051","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2012.09.006","article-title":"Liposomal paclitaxel formulations","volume":"163","author":"Koudelka","year":"2012","journal-title":"J Controlled Release"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0052","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1186\/s12885-018-4888-2","article-title":"Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel","volume":"18","author":"Araki","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.retram.2025.103561_bib0053","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s10637-020-01029-7","article-title":"Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0054","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/10717540601098799","article-title":"Liposome formulation of paclitaxel with enhanced solubility and stability","volume":"14","author":"Yang","year":"2007","journal-title":"Drug Deliv"},{"issue":"2","key":"10.1016\/j.retram.2025.103561_bib0055","first-page":"81","article-title":"Development of liposomal formulations: from concept to clinical investigations","volume":"8","author":"Fan","year":"2013","journal-title":"Asian J Pharmaceut Sci."},{"key":"10.1016\/j.retram.2025.103561_bib0056","first-page":"661","article-title":"Association of genetic polymorphism with taxane-induced peripheral neuropathy: sub-analysis of a randomized phase ii study to determine the optimal dose of 3-week cycle nab-paclitaxel in metastatic breast cancer patients","volume":"76","author":"Abe","year":"2022","journal-title":"Acta Med Okayama"},{"issue":"10","key":"10.1016\/j.retram.2025.103561_bib0057","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s12325-019-01058-6","article-title":"Pharmacokinetics of total and unbound paclitaxel after administration of paclitaxel micellar or nab-paclitaxel: an open, randomized, cross-over, explorative study in breast cancer patients","volume":"36","author":"Borg\u00e5","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.retram.2025.103561_bib0058","first-page":"SP37","article-title":"Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel\/nab-paclitaxel","volume":"27","author":"Brady","year":"2020","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.retram.2025.103561_bib0059","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/OTT.S13836","article-title":"Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval","author":"Yamamoto","year":"2011","journal-title":"Onco Targets Ther"},{"issue":"7","key":"10.1016\/j.retram.2025.103561_bib0060","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1586\/14737140.7.7.919","article-title":"Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy","volume":"7","author":"Henderson","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"10.1016\/j.retram.2025.103561_bib0061","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/CAD.0b013e32830f9046","article-title":"Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status","volume":"19","author":"Desai","year":"2008","journal-title":"Anticancer Drugs"},{"issue":"31","key":"10.1016\/j.retram.2025.103561_bib0062","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil\u2013based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clinical Oncology"},{"issue":"11","key":"10.1016\/j.retram.2025.103561_bib0063","first-page":"6609","article-title":"Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer","volume":"34","author":"Schneeweiss","year":"2014","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0064","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J Controlled Release"},{"key":"10.1016\/j.retram.2025.103561_bib0065","article-title":"Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer","volume":"5","author":"Vishnu","year":"2011","journal-title":"Breast Cancer: Basic Clin Res"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0066","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13046-021-02224-x","article-title":"Targeting ZFP64\/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer","volume":"41","author":"Zhu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.retram.2025.103561_bib0067","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2020.06.025","article-title":"A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells","volume":"491","author":"Rong","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.retram.2025.103561_bib0068","first-page":"805","article-title":"Hsa_circ_0003489 Drives PTX resistance of Human NSCLC cells through modulating miR-98-5p\/IGF2","volume":"16","author":"Xia","year":"2023","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.retram.2025.103561_bib0069","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jss.2022.05.004","article-title":"Circ_0,007,331 Promotes the PTX resistance and progression of breast cancer via miR-200b-3p\/ANLN","volume":"279","author":"Yang","year":"2022","journal-title":"J. Surg. Res."},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0070","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s42003-024-07127-z","article-title":"STUB1 suppresses paclitaxel resistance in ovarian cancer through mediating HOXB3 ubiquitination to inhibit PARK7 expression","volume":"7","author":"Zhao","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.retram.2025.103561_bib0071","article-title":"Co-delivery paclitaxel and IR783 as nanoparticles for potentiated chemo-photothermal-immunotherapy of triple-negative breast cancer","volume":"33","author":"Huang","year":"2025","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.retram.2025.103561_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1175809","article-title":"Immune-related adverse events associated with nab-paclitaxel\/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis","volume":"14","author":"Hao","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.retram.2025.103561_bib0073","doi-asserted-by":"crossref","DOI":"10.21037\/apm-22-690","article-title":"Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis","volume":"11","author":"Lei","year":"2022","journal-title":"Ann Palliat Med"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0074","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41598-019-57380-0","article-title":"Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: a meta-analysis","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.retram.2025.103561_bib0075","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1177\/10600280211058385","article-title":"Adverse event profile for nanoparticle albumin-bound paclitaxel compared with solvent-based taxanes in solid-organ tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"56","author":"He","year":"2022","journal-title":"Ann Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0076","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12885-021-07831-7","article-title":"Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.retram.2025.103561_bib0077","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.7150\/jca.59794","article-title":"Potentially overestimated efficacy of nanoparticle albumin-bound paclitaxel compared with solvent-based paclitaxel in breast cancer: a systemic review and meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1359-6349(10)70002-1","article-title":"Nanoparticle albumin-bound (nab\u2122)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer","volume":"8","author":"Cortes","year":"2010","journal-title":"Eur J Cancer Supplements"},{"issue":"22","key":"10.1016\/j.retram.2025.103561_bib0079","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2217\/fon-2019-0742","article-title":"Nanoparticle albumin-bound paclitaxel\/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients","volume":"16","author":"Fabi","year":"2020","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/nnm-2020-0458","article-title":"Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer","volume":"16","author":"Li","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.retram.2025.103561_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2023.102707","article-title":"Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer","volume":"54","author":"Zhang","year":"2023","journal-title":"Nanomed: Nanotechnol, Biol Med"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0082","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12885-021-08441-z","article-title":"A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer","volume":"21","author":"Lu","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0083","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1186\/s12885-021-08921-2","article-title":"Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases","volume":"21","author":"Xie","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.retram.2025.103561_bib0084","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2147\/DDDT.S79563","article-title":"Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life","author":"Palumbo","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"S8","key":"10.1016\/j.retram.2025.103561_bib0085","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/cncr.35206","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients","volume":"130","author":"Xiong","year":"2024","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.retram.2025.103561_bib0086","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clbc.2011.03.007","article-title":"A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer","volume":"11","author":"Mirtsching","year":"2011","journal-title":"Clin. Breast Cancer"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0087","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.clbc.2013.02.008","article-title":"Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer","volume":"13","author":"Seidman","year":"2013","journal-title":"Clin. Breast Cancer"},{"issue":"22","key":"10.1016\/j.retram.2025.103561_bib0088","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"New England J Med"},{"issue":"8","key":"10.1016\/j.retram.2025.103561_bib0089","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncology"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0090","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jnci\/djab121","article-title":"Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130","volume":"114","author":"Badve","year":"2022","journal-title":"JNCI: J National Cancer Inst"},{"issue":"8","key":"10.1016\/j.retram.2025.103561_bib0091","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: iMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncology"},{"key":"10.1016\/j.retram.2025.103561_bib0092","doi-asserted-by":"crossref","first-page":"v105","DOI":"10.1093\/annonc\/mdx365.080","article-title":"IMpassion131: phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC)","volume":"28","author":"Miles","year":"2017","journal-title":"Ann Oncology"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0093","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12957-024-03424-3","article-title":"Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis","volume":"22","author":"Lin","year":"2024","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.retram.2025.103561_bib0094","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.01.001","article-title":"Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer\u2013A single-arm phase II trial (NeoImmunoboost, AGO-B-041)","volume":"184","author":"Fasching","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0095","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1038\/s41467-023-42479-w","article-title":"Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.retram.2025.103561_bib0096","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","article-title":"Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Research"},{"issue":"6","key":"10.1016\/j.retram.2025.103561_bib0097","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djx258","article-title":"Comparison of neoadjuvant nab-paclitaxel+ carboplatin vs nab-paclitaxel+ gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results","volume":"110","author":"Gluz","year":"2018","journal-title":"JNCI: J National Cancer Institute"},{"key":"10.1016\/j.retram.2025.103561_bib0098","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.09.004","article-title":"Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives","volume":"50","author":"Schettini","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.retram.2025.103561_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117145","article-title":"Protein arginine methyltransferase 5 confers the resistance of triple-negative breast cancer to nanoparticle albumin-bound paclitaxel by enhancing autophagy through the dimethylation of ULK1","volume":"493","author":"Kong","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0100","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1186\/s12885-022-10225-y","article-title":"Basavaraj AK: combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety","volume":"22","author":"Sharmni Vishnu","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0101","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1038\/s41467-022-31704-7","article-title":"A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0102","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyac223","article-title":"Nab-paclitaxel followed by dose-dense epirubicin\/cyclophosphamide in neoadjuvant chemotherapy for triple-negative breast cancer: a phase II study","volume":"28","author":"Liu","year":"2023","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.retram.2025.103561_bib0103","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.14477","article-title":"Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis","volume":"8","author":"Zong","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0104","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s12282-021-01238-9","article-title":"Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)","volume":"28","author":"Futamura","year":"2021","journal-title":"Breast Cancer"},{"issue":"7","key":"10.1016\/j.retram.2025.103561_bib0105","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4103\/jcrt.JCRT_241_19","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer","volume":"15","author":"Yang","year":"2019","journal-title":"J Cancer Res Ther"},{"issue":"7","key":"10.1016\/j.retram.2025.103561_bib0106","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/jjco\/hyv055","article-title":"Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for stage II\/III HER2-negative breast cancer: evaluation of efficacy and safety","volume":"45","author":"Shimada","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0107","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.clbc.2018.01.002","article-title":"Feasibility study of weekly nanoparticle albumin-bound paclitaxel (150 mg\/m2) followed by fluorouracil, epirubicin, and cyclophosphamide therapy as neoadjuvant chemotherapy for HER2-negative breast cancer","volume":"18","author":"Kojima","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.retram.2025.103561_bib0108","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760655","article-title":"Efficacy and safety of albumin-bound paclitaxel compared to docetaxel as neoadjuvant chemotherapy for HER2-negative breast cancer","volume":"11","author":"Lv","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0109","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clbc.2014.02.005","article-title":"Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer","volume":"14","author":"Mr\u00f3zek","year":"2014","journal-title":"Clin. Breast Cancer"},{"issue":"7","key":"10.1016\/j.retram.2025.103561_bib0110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40261-018-0655-z","article-title":"Efficacy and safety of neoadjuvant treatment with bevacizumab, liposomal doxorubicin, cyclophosphamide and paclitaxel combination in locally\/regionally advanced, HER2-negative, grade III at premenopausal status breast cancer: a phase II study","volume":"38","author":"Tampaki","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0111","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","article-title":"Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2\/HER2-negative breast cancer\u2014The evaluating treatment with neoadjuvant abraxane (ETNA) trial: a randomized phase 3 clinical trial","volume":"4","author":"Gianni","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.retram.2025.103561_bib0112","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/nnm-2022-0025","article-title":"Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer","volume":"17","author":"Zhang","year":"2022","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.retram.2025.103561_bib0113","first-page":"1079","article-title":"Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer","volume":"7","author":"Ishigami","year":"2017","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0114","first-page":"457","article-title":"Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study","volume":"82","author":"Shizuku","year":"2020","journal-title":"Nagoya J Med Sci"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clbc.2021.06.006","article-title":"Feasibility study of nanoparticle albumin-bound-paclitaxel and S-1 followed by epirubicin\/cyclophosphamide as neoadjuvant chemotherapy in patients with operable breast cancer: a prospective study","volume":"22","author":"Seki","year":"2022","journal-title":"Clin. Breast Cancer"},{"issue":"8","key":"10.1016\/j.retram.2025.103561_bib0116","first-page":"4213","article-title":"Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer","volume":"34","author":"Ohno","year":"2014","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0117","article-title":"Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis","volume":"26","author":"Peng","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0118","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/annonc\/mdn661","article-title":"Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel)(Abraxane\u00ae) in combination with gemcitabine in patients with metastatic breast cancer (N0531)","volume":"20","author":"Roy","year":"2009","journal-title":"Ann Oncology"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0119","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3892\/ol.2015.2954","article-title":"Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer","volume":"9","author":"Takashima","year":"2015","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0120","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9430952","article-title":"Risk factors for chemotherapy-induced peripheral neuropathy caused by nanoparticle albumin-bound paclitaxel in advanced breast cancer","volume":"2022","author":"Guo","year":"2022","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.retram.2025.103561_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2023.102666","article-title":"Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: a promising treatment option for HER2-low-positive breast cancer","volume":"49","author":"Shi","year":"2023","journal-title":"Nanomed: Nanotechnol, Biol Med"},{"issue":"10","key":"10.1016\/j.retram.2025.103561_bib0122","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3390\/jcm8101689","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel in elderly patients with metastatic breast cancer: a meta-analysis","volume":"8","author":"Li","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0123","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1568009615666150817121731","article-title":"Nab-paclitaxel in metastatic breast cancer: defining the best patient profile","volume":"16","author":"Gonz\u00e1lez-Mart\u00edn","year":"2016","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.retram.2025.103561_bib0124","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/03602532.2025.2485055","article-title":"Genetic determinants of paclitaxel-induced peripheral neuropathy: a review of current literature","volume":"57","author":"Sivadas","year":"2025","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.retram.2025.103561_bib0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/CEOR.S41850","article-title":"An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study","author":"Lazzaro","year":"2013","journal-title":"ClinicoEcon Outcomes Res"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0126","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/erp.13.18","article-title":"Group CW: cost\u2013utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain","volume":"13","author":"Alba","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0127","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3892\/ol.2013.1471","article-title":"Safety of nanoparticle albumin\u2011bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: four case reports","volume":"6","author":"Kimura","year":"2013","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1752-1947-8-6","article-title":"Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report","volume":"8","author":"Cirauqui","year":"2014","journal-title":"J Med Case Rep"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0129","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1159\/000533999","article-title":"Cystoid macular edema following treatment with nanoparticle albumin-bound paclitaxel and atezolizumab for metastatic breast cancer","volume":"16","author":"Yamane","year":"2023","journal-title":"Case Rep Oncol"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/1471-2407-13-232","article-title":"Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients","volume":"13","author":"Tang","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.retram.2025.103561_bib0131","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3389\/fphar.2018.01372","article-title":"Ding Y: tolerance, variability and pharmacokinetics of albumin-bound paclitaxel in chinese breast cancer patients","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.retram.2025.103561_bib0132","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1021\/acs.molpharmaceut.9b01221","article-title":"Albumin nanoparticle of paclitaxel (Abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer","volume":"17","author":"Yuan","year":"2020","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0133","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12962-024-00578-5","article-title":"Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from US perspective","volume":"22","author":"Shao","year":"2024","journal-title":"Cost Effectiveness Resource Allocation"},{"key":"10.1016\/j.retram.2025.103561_bib0134","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CEOR.S82194","article-title":"Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective","author":"Dranitsaris","year":"2015","journal-title":"ClinicoEconomics Outcomes Res"},{"key":"10.1016\/j.retram.2025.103561_bib0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.vhri.2021.04.003","article-title":"Cost-effectiveness of nab-paclitaxel and gemcitabine versus gemcitabine monotherapy for patients with unresectable metastatic pancreatic cancer in Japan","volume":"28","author":"Morimoto","year":"2022","journal-title":"Value Health Reg Issues"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0136","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14737167.2020.1812386","article-title":"Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china","volume":"21","author":"Cui","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0137","first-page":"379","article-title":"Safety and efficacy of low-dose nanoparticle albumin-bound paclitaxel for HER2-negative metastatic breast cancer","volume":"38","author":"Takashima","year":"2018","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.retram.2025.103561_bib0138","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1016\/j.celrep.2017.11.096","article-title":"PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression","volume":"21","author":"Chiang","year":"2017","journal-title":"Cell Rep"},{"issue":"551","key":"10.1016\/j.retram.2025.103561_bib0139","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.retram.2025.103561_bib0140","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-017-4597-6","article-title":"PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer","volume":"168","author":"Wang","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0141","article-title":"Tetrahydrocurcumin chemosensitizes breast cancer to albumin-bound paclitaxel by enhancing SPARC expression through demethylation","volume":"2022","author":"Qiu","year":"2022","journal-title":"J Oncol"},{"issue":"4","key":"10.1016\/j.retram.2025.103561_bib0142","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3816\/CBC.2010.n.036","article-title":"Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer","volume":"10","author":"Conlin","year":"2010","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0143","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13058-019-1186-0","article-title":"A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)","volume":"21","author":"Patel","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0144","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12885-022-09346-1","article-title":"Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0\/N1mi, HER2+ early breast cancer (PHAEDRA)","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0145","doi-asserted-by":"crossref","first-page":"e1687","DOI":"10.1002\/ctm2.1687","volume":"14","author":"Man","year":"2024","journal-title":"Clin Transl Med"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0146","doi-asserted-by":"crossref","first-page":"654","DOI":"10.21037\/gs-24-81","article-title":"The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study","volume":"13","author":"Wang","year":"2024","journal-title":"Gland Surg"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0147","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clbc.2014.12.003","article-title":"Phase II study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer","volume":"15","author":"Tanaka","year":"2015","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.retram.2025.103561_bib0148","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1093\/oncolo\/oyad160","article-title":"A phase II study of neoadjuvant PLD\/cyclophosphamide and sequential nab-Paclitaxel Plus Dual HER2 blockade in HER2-positive breast cancer","volume":"29","author":"Yang","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.retram.2025.103561_bib0149","first-page":"579","article-title":"Efficacy and safety of neoadjuvant chemotherapy containing nanoparticle albumin-bound paclitaxel (NabPTX) in operable human epidermal growth factor receptor 2-positive breast cancer","volume":"43","author":"Yoshioka","year":"2016","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.retram.2025.103561_bib0150","first-page":"1969","article-title":"Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer","author":"Huang","year":"2015","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0151","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto\u2014GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncology"},{"issue":"25","key":"10.1016\/j.retram.2025.103561_bib0152","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69\u2013GeparSepto","volume":"37","author":"Untch","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.retram.2025.103561_bib0153","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-017-4200-1","article-title":"Efficacy and safety of nab-paclitaxel 125 mg\/m2 and nab-paclitaxel 150 mg\/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)","volume":"163","author":"Furlanetto","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.retram.2025.103561_bib0154","series-title":"Event-Free Survival Analysis of the Prospectively Randomized Phase III Etna Study with Neoadjuvant Nab-Paclitaxel (nab-P) Versus Paclitaxel (P) Followed by Anthracycline Regimens in Women with HER2-Negative High-Risk Breast Cancer","author":"Gianni","year":"2019"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:52:24Z","timestamp":1775065944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318625000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":154,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2452318625000704"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2025.103561","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel): Bridging pharmacology and translational medicine in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2025.103561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103561"}}